Cannabis use preferences in women with myofascial pelvic pain: A cross-sectional study
- PMID: 37095765
- PMCID: PMC10121619
- DOI: 10.1016/j.eurox.2023.100192
Cannabis use preferences in women with myofascial pelvic pain: A cross-sectional study
Abstract
Objective: Myofascial tenderness is present in most chronic pelvic pain conditions and causes significant distress to patients. Treatment is challenging and often not curative. Cannabis is often used for self-management of chronic pelvic pain. However, we do not know which concentrations and routes of administration are most acceptable to users. We aimed to investigate patterns and willingness of cannabis product use among both habitual users and non-users with myofascial pelvic pain (MPP), to inform therapeutic development.
Study design: We conducted a cross-sectional study of questionnaire responses from female patients with MPP from two tertiary pelvic pain centers. We aimed for a convenience sample of 100 responses with representation from both centers. Inclusion criteria were age over 18 with pelvic floor muscle tenderness on standard gynecologic examination. We collected information on demographics, pelvic pain history, cannabis use status, cannabis use preferences, validated opioid misuse risk assessment, and interest in using gynecologic cannabis products and used descriptive analyses.
Results: 77/135 (57 %) questionnaire respondents were cannabis users and 58 (43 %) were non-users. Most users consume cannabis daily, (48.1 %) orally (66.2 %) or by smoking (60.7 %), and rated cannabis as effective at relieving pelvic pain. 37/58 (63.8 %) non-cannabis users responded that they would be willing to use cannabis for pelvic pain. Lack of information and potential adverse effects were the most common reasons for unwillingness to use. Approximately 3 of 4 respondents were willing to try vaginal or vulvar application of cannabis products for pelvic pain.
Conclusions: This cross-sectional study describes cannabis use patterns in MPP patients. Topical vulvar and vaginal cannabis products are of strong interest to both cannabis users and non-users and warrant further research.
Keywords: Cannabis; Chronic pelvic pain; Myofascial pelvic pain; Vaginal suppository; Vulvar cream.
Copyright©2023PublishedbyElsevierB.V.
Conflict of interest statement
MG received the D.A. Boyes Memorial Research Award which partially funded this project. AB has received compensation related to his research through Emerald Health Therapeutics and Ascension Sciences. The other authors have no relevant conflicts of interest.
Figures
Similar articles
-
Pelvic floor myofascial pain severity and pelvic floor disorder symptom bother: is there a correlation?Am J Obstet Gynecol. 2019 Sep;221(3):235.e1-235.e15. doi: 10.1016/j.ajog.2019.07.020. Epub 2019 Jul 15. Am J Obstet Gynecol. 2019. PMID: 31319079 Free PMC article.
-
Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain.Obstet Gynecol. 2021 Jan 1;137(1):91-99. doi: 10.1097/AOG.0000000000004207. Obstet Gynecol. 2021. PMID: 33278297
-
Prevalence of urinary, prolapse, and bowel symptoms in Mayer-Rokitansky-Küster-Hauser syndrome.Am J Obstet Gynecol. 2021 Jul;225(1):70.e1-70.e12. doi: 10.1016/j.ajog.2021.02.020. Epub 2021 Feb 20. Am J Obstet Gynecol. 2021. PMID: 33621544
-
Physical examination techniques for the assessment of pelvic floor myofascial pain: a systematic review.Am J Obstet Gynecol. 2018 Nov;219(5):497.e1-497.e13. doi: 10.1016/j.ajog.2018.06.014. Epub 2018 Jun 28. Am J Obstet Gynecol. 2018. PMID: 29959930 Free PMC article.
-
[Myofascial chronic pelvic pain in women : A retrospective evaluation of the effects of specific diagnostics and therapy].Schmerz. 2020 Oct;34(5):388-399. doi: 10.1007/s00482-020-00488-4. Schmerz. 2020. PMID: 32725502 Review. German.
Cited by
-
Medical Cannabis Prescription Practices and Quality of Life in Thai Patients: A Nationwide Prospective Observational Cohort Study.Med Cannabis Cannabinoids. 2024 Jul 17;7(1):125-137. doi: 10.1159/000540153. eCollection 2024 Jan-Dec. Med Cannabis Cannabinoids. 2024. PMID: 39144529 Free PMC article.
-
Optimization and Evaluation of Cannabis-Based Magistral Formulations: A Path to Personalized Therapy.Pharmaceuticals (Basel). 2025 Jan 9;18(1):73. doi: 10.3390/ph18010073. Pharmaceuticals (Basel). 2025. PMID: 39861136 Free PMC article.
-
Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson's disease: A French survey.Clin Park Relat Disord. 2024 Nov 20;11:100286. doi: 10.1016/j.prdoa.2024.100286. eCollection 2024. Clin Park Relat Disord. 2024. PMID: 39687323 Free PMC article.
References
-
- Manz J., Hyakutake M., Kelly E. Calling for openness to the study of cannabis use in chronic pelvic pain. J Obstet Gynecol Can. 2020;43(5):611–613. - PubMed
-
- Ross V., Detterman C., Hallisey A. Myofascial pelvic pain: an overlooked and treatable cause of chronic pelvic pain. J Midwifery Women's Health. 2021;66(2):148–160. - PubMed
-
- Gyang A., Hartman M., Lamvu G. Musculoskeletal causes of chronic pelvic pain: what a gynecologist should know. Obstet Gynecol. 2013;121:645–650. - PubMed
-
- Bo K., Frawley H.C., Haylen B.T., et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Int Urogynecol J. 2017;28(2):191–213. - PubMed
LinkOut - more resources
Full Text Sources